The goal of this Core is to provide the analytical tools and statistical and computational expertise needed to design and analyze the high throughput experiments and data generated by the Projects and Cores of this POI. Additionally, this Core will integrate the data resulting from the Project with external cancer genome data such as that generated by The Cancer Genome Atlas (TCGA) project, in order to elucidate the mechanism(s) of drug resistance.
The Specific Aims of Core 3 are (1) to perform genomic characterization of human and mouse cancer genomes and integrating these data to identify events that cause resistance;(2) Analyze the shRNA and drug response data to identify dependencies in pre-treatment and relapsed cells;(3) Integrate data from this P01 with comprehensive genomic data generated by The Cancer Genome Atlas (TCGA) project to increase statistical power. At the end of the funded period, integrative analysis of all data produced within this P01 and external data will yield a clear set of hypotheses regarding candidate genes, pathways and drugs that are involved in and can affect the development of drug resistance in BRAF-mutant melanoma.
|Alves, Cleidson P; Yokoyama, Satoro; Goedert, Lucas et al. (2016) MYO5A gene is a target of MITF in melanocytes. J Invest Dermatol :|
|Kryukov, Gregory V; Wilson, Frederick H; Ruth, Jason R et al. (2016) MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351:1214-8|
|Xia, Yun; Li, Ying; Westover, Kenneth D et al. (2016) Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and Î±-Mangostin. PLoS One 11:e0155217|
|Wang, Hequn; Osseiran, Sam; Igras, Vivien et al. (2016) In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin. Sci Rep 6:37986|
|Tirosh, Itay; Izar, Benjamin; Prakadan, Sanjay M et al. (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352:189-96|
|Shen, Che-Hung; Kim, Sun Hye; Trousil, Sebastian et al. (2016) Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med 22:1056-61|
|Friedman, Adam A; Amzallag, Arnaud; Pruteanu-Malinici, Iulian et al. (2015) Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One 10:e0140310|
|Kumar, Raj; Taylor, Michael; Miao, Benchun et al. (2015) BAP1 has a survival role in cutaneous melanoma. J Invest Dermatol 135:1089-97|
|Kwong, Lawrence N; Boland, Genevieve M; Frederick, Dennie T et al. (2015) Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest 125:1459-70|
|Zheng, Bin; Fisher, David E (2015) Metabolic vulnerability in melanoma: a ME2 (me too) story. J Invest Dermatol 135:657-9|
Showing the most recent 10 out of 49 publications